Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

ConditionsMalignant Solid Tumors Primary Brain Tumor Melanoma Soft Tissue Sarcoma Colorectal Cancer Kidney Cancer Prostate Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age1+

SponsorN.N. Petrov National Medical Research Center of Oncology

About this trial

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

Eligibility criteria

Qualifiers

Signed inform consent

Histolgically verified solid tumour

Receiving systemic therapy for neoplasm

Has archival tumour tissue

Disqualifiers

Concurrent Lymphoprolipherative disorder

Patients after stem cell or bone marrow thansplantation

Incomplete informaton on previous cancer history or medical history

Patients with known primary immunodeficiency

Trial design

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants

are grouped into 7 trial groups

Trial groups

See each trial group below.

Locations

N.N. Petrov NMRC of Oncology, Oncoimmunology dep.197758, Saint Petersburg Russia

Sponsors and collaborators

N.N. Petrov National Medical Research Center of Oncology

Lead sponsor

Source ClinicalTrials.gov